{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T05:27:33Z","timestamp":1792301253249,"version":"4.4.0"},"reference-count":125,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T00:00:00Z","timestamp":1604361600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Conclusions from previously reported articles have revealed that many commonly used pharmaceutical excipients, known to be pharmacologically inert, show effects on drug transporters and\/or metabolic enzymes. Thus, the pharmacokinetics (absorption, distribution, metabolism and elimination) of active pharmaceutical ingredients are possibly altered because of their transport and metabolism modulation from the incorporated excipients. The aim of this review is to present studies on the interaction of various commonly-used excipients on pre-systemic metabolism by CYP450 enzymes. Excipients such as surfactants, polymers, fatty acids and solvents are discussed. Based on all the reported outcomes, the most potent inhibitors were found to be surfactants and the least effective were organic solvents. However, there are many factors that can influence the inhibition of CYP450, for instance type of excipient, concentration of excipient, type of CYP450 isoenzyme, incubation condition, etc. Such evidence will be very useful in dosage form design, so that the right formulation can be designed to maximize drug bioavailability, especially for poorly bioavailable drugs.<\/jats:p>","DOI":"10.3390\/ijms21218224","type":"journal-article","created":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T09:09:32Z","timestamp":1604394572000},"page":"8224","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":105,"title":["Pharmaceutical Excipients and Drug Metabolism: A Mini-Review"],"prefix":"10.3390","volume":"21","author":[{"given":"Rahul","family":"Patel","sequence":"first","affiliation":[{"name":"Drug Discovery, Delivery and Patient Care (DDDPC), School of Life Sciences, Pharmacy and Chemistry, Kingston University, Kingston upon Thames, Surrey KT1 2EE, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5863-9400","authenticated-orcid":false,"given":"James","family":"Barker","sequence":"additional","affiliation":[{"name":"Drug Discovery, Delivery and Patient Care (DDDPC), School of Life Sciences, Pharmacy and Chemistry, Kingston University, Kingston upon Thames, Surrey KT1 2EE, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5058-0256","authenticated-orcid":false,"given":"Amr","family":"ElShaer","sequence":"additional","affiliation":[{"name":"Drug Discovery, Delivery and Patient Care (DDDPC), School of Life Sciences, Pharmacy and Chemistry, Kingston University, Kingston upon Thames, Surrey KT1 2EE, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,11,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S1461-5347(00)00247-9","article-title":"Recent technological advances in oral drug delivery\u2014A review","volume":"3","author":"Sastry","year":"2000","journal-title":"Pharm. Sci. Technol. Today"},{"key":"ref_2","unstructured":"(2020, July 24). Major Advances in Oral Drug Delivery over the Past 15 Years. Available online: https:\/\/www.americanpharmaceuticalreview.com\/Featured-Articles\/148747-Major-Advances-in-Oral-Drug-Delivery-over-the-Past-15-Years\/."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1208\/s12248-016-9928-8","article-title":"The Effects of Pharmaceutical Excipients on Gastrointestinal Tract Metabolic Enzymes and Transporters\u2014An Update","volume":"18","author":"Zhang","year":"2016","journal-title":"AAPS PharmSciTech"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s40262-015-0242-x","article-title":"Oral Bioavailability: Issues and Solutions via Nanoformulations","volume":"54","author":"Pathak","year":"2015","journal-title":"Clin. Pharmacokinet."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0169-409X(00)00061-2","article-title":"Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption","volume":"42","author":"Ezra","year":"2000","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s00198-005-1911-7","article-title":"Absorption of the oral bisphosphonate alendronate in osteoporotic patients with Crohn\u2019s disease","volume":"16","author":"Cremers","year":"2005","journal-title":"Osteoporos. Int."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1196\/annals.1365.036","article-title":"Women\u2019s health and disease: Gynaecologic, endocrine, and reproductive issues","volume":"1092","author":"Lambrinoudaki","year":"2006","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_8","first-page":"593","article-title":"Preclinical pharmacokinetics of statins","volume":"24","author":"Reinoso","year":"2002","journal-title":"Clin. Exp. Pharmacol, Physiol."},{"key":"ref_9","first-page":"457","article-title":"Clinical pharmacokinetics of statins","volume":"24","author":"Garcia","year":"2003","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"168","DOI":"10.2337\/diaclin.21.4.168","article-title":"Statin Treatment in Diabetes Mellitus","volume":"21","author":"Buse","year":"2003","journal-title":"Clin. Diabetes"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1248\/bpb.26.501","article-title":"Transdermal Administration of Bromocriptine","volume":"26","author":"Degim","year":"2003","journal-title":"Biol. Pharm. Bull."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0003-2670(03)00406-9","article-title":"Prediction of drug bioavailability based on molecular structure","volume":"485","author":"Turner","year":"2003","journal-title":"Anal. Chim. Acta"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0928-0987(00)00099-3","article-title":"Bisphosphonate prodrugs: Synthesis and in vitro evaluation of alkyl and acyloxymethyl esters of etidronic acid as bioreversible prodrugs of etidronate","volume":"11","author":"Niemi","year":"2000","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_14","first-page":"10","article-title":"Cross-linked nanoparticles of cytarabine: Encapsulation, storage and in vivo release","volume":"1","author":"Joseph","year":"2007","journal-title":"Afr. J. Pharm. Pharmacol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.coph.2006.07.004","article-title":"Making a case for domperidone in the treatment of gastrointestinal motility disorders","volume":"6","author":"Ahmad","year":"2006","journal-title":"Curr. Opin. Pharmcol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3109\/07357900009031824","article-title":"Hepatic Enzyme Induction with Phenobarbital and Doxorubicin Metabolism and Myelotoxicity in the Rabbit","volume":"18","author":"Sturgill","year":"2000","journal-title":"Cancer Investig."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0278-6915(02)00209-0","article-title":"Human variability in CYP3A4 metabolism and CYP3A4-related uncertainty factors for risk assessment","volume":"41","author":"Dorne","year":"2003","journal-title":"Food. Chem. Toxicol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/BF00543970","article-title":"Pharmacokinetics of PN 200-110 (isradipine), a new calcium antagonist, after oral administration in man","volume":"32","author":"Tse","year":"1987","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/BF02968580","article-title":"Enhanced nimodipine bioavailability after oral administration of nimodipine with morin, a flavonoid, in rabbits","volume":"29","author":"Choi","year":"2006","journal-title":"Arch. Pharm. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1191\/0269216302pm584oa","article-title":"Using anti-muscarinic drugs in the management of death rattle: Evidence-based guidelines for palliative care","volume":"16","author":"Bennett","year":"2002","journal-title":"Palliat. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1097\/00000542-199212000-00022","article-title":"Metabolism of Ketamine Stereoisomers by Human Liver Microsomes","volume":"77","author":"Kharasch","year":"1992","journal-title":"Anesthesiology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1017\/S0265021506000731","article-title":"Evaluation of the pharmacokinetic profile and analgesic efficacy of oral morphine after total hip arthroplasty","volume":"23","author":"Manoir","year":"2006","journal-title":"Eur. J. Anaesthesiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/BF00636797","article-title":"Pharmacokinetics and oral bioavailability of pyridostigmine in man","volume":"18","author":"Aquilonius","year":"1980","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_24","first-page":"435","article-title":"Pharmacokinetics of naloxone: An insight into the locus of effect on stress-ulceration","volume":"251","author":"Adair","year":"1989","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1177\/0091270005281044","article-title":"Bioavailability and Metabolism of Prochlorperazine Administered via the Buccal and Oral Delivery Route","volume":"45","author":"Finn","year":"2005","journal-title":"J. Clin. Pharmacol."},{"key":"ref_26","first-page":"349","article-title":"Selegiline orally disintegrating tablet in the treatment of Parkinson\u2019s disease","volume":"3","author":"Clarke","year":"2006","journal-title":"Therapy"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1023\/A:1020601906027","article-title":"Mixed effect modelling of sumatriptan pharmacokinetics during drug development: II. From healthy subjects to phase 2 dose ranging in patients","volume":"27","author":"Cossons","year":"1999","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"719","DOI":"10.2165\/00003088-200241100-00003","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Cholinesterase Inhibitors","volume":"41","author":"Jann","year":"2002","journal-title":"Clin. Pharmacokinet."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"505","DOI":"10.4103\/0250-474X.36934","article-title":"Studies on buccoadhesive tablets of terbutaline sulphate","volume":"69","author":"Nakhat","year":"2007","journal-title":"Indian J. Pharm. Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/j.1742-7843.2006.pto_482.x","article-title":"Effect of fluvoxamine and erythromycin on the pharmaco- kinetics of oral lidocaine","volume":"99","author":"Isohanni","year":"2006","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/1479-7364-4-1-59","article-title":"The cytochrome P450 homepage","volume":"4","author":"Nelson","year":"2009","journal-title":"Hum. Genomics"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s00216-008-2291-6","article-title":"Functional pharmacogenetics\/genomics of human cytochromes P450 involved in drug biotransformation","volume":"392","author":"Zanger","year":"2008","journal-title":"Anal. Bioanal. Chem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/med.21533","article-title":"Lipidic prodrug approach for improved oral drug delivery and therapy","volume":"39","author":"Markovic","year":"2018","journal-title":"Med. Res. Rev."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1124\/pr.110.003459","article-title":"Prodrugs\u2014from Serendipity to Rational Design","volume":"63","author":"Huttunen","year":"2011","journal-title":"Pharmacol. Rev."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.2147\/DDDT.S68909","article-title":"Provisional in-silico biopharmaceutics classification (BCS) to guide oral drug product development","volume":"8","author":"Dahan","year":"2014","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nrd2468","article-title":"Prodrugs: Design and clinical applications","volume":"7","author":"Rautio","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.drudis.2013.08.014","article-title":"Chemistry-enabled drug delivery (prodrugs): Recent progress and challenges","volume":"19","author":"Clas","year":"2014","journal-title":"Drug Discov. Today"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1734-1140(13)70959-9","article-title":"Prodrugs: A challenge for the drug development","volume":"65","author":"Zawilska","year":"2013","journal-title":"Curr. Pharmacol. Rep."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"16489","DOI":"10.3390\/molecules191016489","article-title":"Modern Prodrug Design for Targeted Oral Drug Delivery","volume":"19","author":"Dahan","year":"2014","journal-title":"Molecules"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1208\/ps020106","article-title":"Targeted prodrug design to optimize drug delivery","volume":"2","author":"Han","year":"2000","journal-title":"AAPS PharmSciTech"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1002\/jps.2600691203","article-title":"Improving intestinal absorption of water-insoluble compounds: A membrane metabolism strategy","volume":"69","author":"Amidon","year":"1980","journal-title":"J. Pharm. Sci."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"4755","DOI":"10.1002\/jps.22205","article-title":"Prodrugs: Some Thoughts and Current Issues","volume":"99","author":"Stella","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jconrel.2014.08.004","article-title":"Pre-systemic metabolism of orally administered drugs and strategies to overcome it","volume":"192","year":"2014","journal-title":"J. Control. Release"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1046\/j.1365-2125.1998.00764.x","article-title":"Grapefruit juice\u2013drug interactions","volume":"46","author":"Bailey","year":"1998","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/jps.23382","article-title":"Flavonoids and Polymer Derivatives as CYP3A4 Inhibitors for Improved Oral Drug Bioavailability","volume":"102","author":"Fasinu","year":"2013","journal-title":"J. Pharm. Sci."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1124\/jpet.104.079608","article-title":"The Grapefruit Juice Effect Is Not Limited to Cytochrome P450 (P450) 3A4: Evidence for Bergamottin-Dependent Inactivation, Heme Destruction, and Covalent Binding to Protein in P450s 2B6 and 3A5","volume":"313","author":"Lin","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1006\/abbi.2000.1835","article-title":"Inhibition Selectivity of Grapefruit Juice Components on Human Cytochromes P450","volume":"378","author":"Tassaneeyakul","year":"2000","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1016\/j.bmc.2005.11.039","article-title":"Furocoumarins from grapefruit juice and their effect on human CYP 3A4 and CYP 1B1 isoenzymes","volume":"14","author":"Girennavar","year":"2006","journal-title":"Bioorg. Med. Chem."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1124\/dmd.104.000547","article-title":"Two Major Grapefruit Juice Components Differ in Intestinal CYP3A4 Inhibition Kinetic and Binding Properties","volume":"32","author":"Paine","year":"2004","journal-title":"Drug Metab. Dispos."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1124\/jpet.104.076836","article-title":"Two Major Grapefruit Juice Components Differ in Time to Onset of Intestinal CYP3A4 Inhibition","volume":"312","author":"Paine","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0009-9236(03)00118-8","article-title":"Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice","volume":"74","author":"Greenblatt","year":"2003","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1038\/sj.bjp.0703433","article-title":"Effect of furanocoumarin derivatives in grapefruit juice on the uptake of vinblastine by Caco-2 cells and on the activity of cytochrome P450 3A4","volume":"130","author":"Ohnishi","year":"2000","journal-title":"Br. J. Pharmacol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1046\/j.1365-2125.1999.00052.x","article-title":"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components","volume":"48","author":"Eagling","year":"2001","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1248\/bpb.20.560","article-title":"Grapefruit Component Interacting with Rat and Human P450 CYP3A: Possible Involvement of Non-Flavonoid Components in Drug Interaction","volume":"20","author":"Fukuda","year":"1997","journal-title":"Biol. Pharm. Bull."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1517\/17425255.2011.553189","article-title":"The effect of grapefruit juice on drug disposition","volume":"7","author":"Hanley","year":"2011","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"28","DOI":"10.2133\/dmpk.25.28","article-title":"Contribution of Intestinal Cytochrome P450-Mediated Metabolism to Drug-Drug Inhibition and Induction Interactions","volume":"25","author":"Galetin","year":"2010","journal-title":"Drug Metab. Pharmacokinet."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1002\/jps.23443","article-title":"Presystemic Metabolism of AZ\u20190908, A Novel mPGES-1 Inhibitor: An In Vitro and In Vivo Cross-Species Comparison","volume":"102","author":"Bylund","year":"2013","journal-title":"J. Pharm. Sci."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2165\/00003088-200544030-00005","article-title":"Mechanism-Based Inhibition of Cytochrome P450 3A4 by Therapeutic Drugs","volume":"44","author":"Zhou","year":"2005","journal-title":"Clin. Pharmacokinet."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1365-2036.2005.02714.x","article-title":"Review article: Similarities and differences among delayed-release proton-pump inhibitor formulations","volume":"22","author":"Horn","year":"2005","journal-title":"Aliment. Pharm. Ther."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0168-3659(96)01536-2","article-title":"Mucoadhesive polymers in peroral peptide drug delivery. IV. Polycarbophil and chitosan are potent enhancers of peptide transport across intestinal mucosae in vitro","volume":"45","author":"Rentel","year":"1997","journal-title":"J. Control. Release"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.ejpb.2008.03.019","article-title":"Pharmaceutical excipients inhibit cytochrome P450 activity in cell free systems and after systemic administration","volume":"70","author":"Ren","year":"2008","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1002\/hep.20948","article-title":"Acetaminophen-induced acute liver failure: Results of a United States multicenter, prospective study","volume":"42","author":"Larson","year":"2005","journal-title":"Hepatology"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"341a","DOI":"10.1126\/science.298.5592.341a","article-title":"TOXICOLOGY: Protecting Liver from Painkiller\u2019s Lethal Dose","volume":"298","author":"Marx","year":"2002","journal-title":"Science"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1006\/taap.1998.8501","article-title":"Protection against Acetaminophen Toxicity in CYP1A2 and CYP2E1 Double-Null Mice","volume":"152","author":"Zaher","year":"1998","journal-title":"Toxicol. Appl. Pharm."},{"key":"ref_65","unstructured":"USP A. (2020, July 24). Acetaminophen Oral Solution USP\u2014PAI, Available online: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4383763\/."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"43","DOI":"10.15415\/jptrm.2013.11004","article-title":"Surfactants: Pharmaceutical and Medicinal Aspects","volume":"1","author":"Sekhon","year":"2013","journal-title":"JPTRM"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S0959-8049(01)00171-X","article-title":"Cremophor EL","volume":"37","author":"Gelderblom","year":"2001","journal-title":"Eur. J. Cancer"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ejpb.2010.12.033","article-title":"Effects of non-ionic surfactants on cytochrome P450-mediated metabolism in vitro","volume":"78","author":"Christiansen","year":"2011","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/jps.21836","article-title":"Absorption Barriers in the Rat Intestinal Mucosa. 3: Effects of Polyethoxylated Solubilizing Agents on Drug Permeation and Metabolism","volume":"99","author":"Mudra","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1002\/jps.10176","article-title":"A comparison of commonly used polyethoxylated pharmaceutical excipients on their ability to inhibit P-glycoprotein activity in vitro","volume":"91","author":"Hugger","year":"2002","journal-title":"J. Pharm. Sci."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1002\/jps.10175","article-title":"Effects of Poly(ethylene glycol) on Efflux Transporter Activity in Caco-2 Cell Monolayers","volume":"91","author":"Hugger","year":"2002","journal-title":"J. Pharm. Sci."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1046\/j.1432-1327.1999.00037.x","article-title":"Membrane fluidization by ether, other anesthetics, and certain agents abolishes P-glycoprotein ATPase activity and modulates efflux from multidrug-resistant cells","volume":"259","author":"Regev","year":"1999","journal-title":"Eur. J. Biochem."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0928-0987(02)00055-6","article-title":"Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers","volume":"16","author":"Rege","year":"2002","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s11626-011-9449-9","article-title":"Evaluation of surfactants as solubilizing agents in microsomal metabolism reactions with lipophilic substrates. In Vitro Cell","volume":"47","author":"Randall","year":"2011","journal-title":"Dev. Biol. Anim."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/bdd.383","article-title":"In vitro investigation on the impact of the surface-active excipients Cremophor EL, Tween 80 and Solutol HS 15 on the metabolism of midazolam","volume":"25","author":"Huwyler","year":"2004","journal-title":"Biopharm. Drug. Dispos."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/BF00689193","article-title":"Metabolism of taxol by human and rat liver in vitro: A screen for drug interactions and interspecies differences","volume":"36","author":"Klecker","year":"1995","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0009-9236(03)00059-6","article-title":"Pharmacokinetic and pharmaceutic interaction between digoxin and Cremophor RH40","volume":"73","author":"Tayrouz","year":"2003","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1007\/s11596-010-0543-0","article-title":"Inhibitive effect of cremophor RH40 or tween 80-based self-microemulsifying drug delivery system on cytochrome P450 3A enzymes in murine hepatocytes","volume":"30","author":"Rao","year":"2010","journal-title":"J. Huazhong Univ. Sci. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/FPC.0b013e32831665ea","article-title":"Inhibition of CYP3A4 expression by ketoconazole is mediated by the disruption of pregnane X receptor, steroid receptor coactivator-1, and hepatocyte nuclear factor 4alpha interaction","volume":"19","author":"Lim","year":"2009","journal-title":"Pharmacogenet. Genom."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1124\/jpet.108.142091","article-title":"Contribution of down-regulation of intestinal and hepatic cytochrome P450 3A to increased absorption of cyclosporine A in a rat nephrosis model","volume":"327","author":"Fujita","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1007\/s12272-001-1171-z","article-title":"In vitro metabolic stability of moisture-sensitive rabeprazole in human liver microsomes and its modulation by pharmaceutical excipients","volume":"31","author":"Ren","year":"2008","journal-title":"Arch. Pharm. Res."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Farsang, E., Ga\u00e1l, V., Horv\u00e1th, O., B\u00e1rdos, E., and Horv\u00e1th, K. (2019). Analysis of Non-Ionic Surfactant Triton X-100 Using Hydrophilic Interaction Liquid Chromatography and Mass Spectrometry. Molecules, 24.","DOI":"10.3390\/molecules24071223"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.tiv.2004.04.006","article-title":"Interaction of non-ionic surfactants with hepatic CYP in Prochilodus scrofa","volume":"18","author":"Meirelles","year":"2004","journal-title":"Toxicol. In Vitro"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jsps.2015.02.025","article-title":"A review of polymers as multifunctional excipients in drug dosage form technology","volume":"24","author":"Karolewicz","year":"2016","journal-title":"Saudi Pharm. J."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ijpharm.2018.09.052","article-title":"In vitro effect of mPEG2k-PCLx micelles on rat liver cytochrome P450 enzymes","volume":"552","author":"Qiu","year":"2018","journal-title":"Int. J. Pharm."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1021\/mp400175n","article-title":"Mediation of in Vitro Cytochrome P450 Activity by Common Pharmaceutical Excipients","volume":"10","author":"Martin","year":"2013","journal-title":"Mol. Pharm."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ijpharm.2007.12.028","article-title":"Effect of pluronic F68 block copolymer on P-glycoprotein transport and CYP3A4 metabolism","volume":"356","author":"Huang","year":"2008","journal-title":"Int. J. Pharm."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1208\/ps040440","article-title":"An in vitro examination of the impact of polyethylene glycol 400, pluronic P85, and vitamin E d-a-tocopheryl polyethylene glycol 1000 succinate on P-glycoprotein efflux and enterocyte-based metabolism in excised rat intestine","volume":"4","author":"Johnson","year":"2002","journal-title":"AAPS PharmSciTech"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Butt, U., ElShaer, A., Snyder, L., Al-Kinani, A., Le Gresley, A., and Alany, R. (2018). Fatty Acid Based Microemulsions to Combat Ophthalmia Neonatorum Caused by Neisseria gonorrhoeae and Staphylococcus aureus. Nanomaterials, 8.","DOI":"10.3390\/nano8010051"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1128\/AAC.45.11.3209-3212.2001","article-title":"In Vitro Killing of Candida albicans by Fatty Acids and Monoglycerides","volume":"45","author":"Bergsson","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Yoon, B., Jackman, J., Valle-Gonz\u00e1lez, E., and Cho, N. (2018). Antibacterial Free Fatty Acids and Monoglycerides: Biological Activities, Experimental Testing, and Therapeutic Applications. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19041114"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1128\/AAC.2.1.23","article-title":"Fatty Acids and Derivatives as Antimicrobial Agents","volume":"2","author":"Kabara","year":"1972","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/BF02570908","article-title":"Antimicrobial lipids: Natural and synthetic fatty acids and monoglycerides","volume":"12","author":"Kabara","year":"1977","journal-title":"Lipids"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/BF02678802","article-title":"Antimicrobial agents derived from fatty acids","volume":"61","author":"Kabara","year":"1984","journal-title":"J. Am. Oil Chem. Soc."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1128\/AAC.2.6.492","article-title":"Relationship of Chemical Structure and Antimicrobial Activity of Alkyl Amides and Amines","volume":"2","author":"Kabara","year":"1972","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ejps.2017.01.027","article-title":"Inhibition of cytochrome P450 enzymes by saturated and unsaturated fatty acids in human liver microsomes, characterization of enzyme kinetics in the presence of bovine serum albumin (0.1 and 1.0% w\/v) and in vitro\u2014in vivo extrapolation of hepatic clearance","volume":"101","author":"Palacharla","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"9497","DOI":"10.1074\/jbc.M312516200","article-title":"Structure of Human Microsomal Cytochrome P450 2C8","volume":"279","author":"Schoch","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1124\/pr.115.011411","article-title":"Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions","volume":"68","author":"Backman","year":"2015","journal-title":"Pharmacol. Rev."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1016\/j.lfs.2006.08.016","article-title":"The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes","volume":"79","author":"Yao","year":"2006","journal-title":"Life Sci."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/0003-9861(95)90023-3","article-title":"Arachidonic acid metabolism by human cytochrome P450s 2C8, 2C9, 2E1, and 1A2: Regioselective oxygenation and evidence for a role for CYP2C enzymes in arachidonic acid epoxygenation in human liver microsomes","volume":"320","author":"Rifkind","year":"1995","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1080\/004982599238632","article-title":"Effects of arachidonic acid, prostaglandins, retinol, retinoic acid and cholecalciferol on xenobiotic oxidations catalysed by human cytochrome P450 enzymes","volume":"29","author":"Yamazaki","year":"1999","journal-title":"Xenobiotica"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1177\/0960327106071979","article-title":"Evaluation of the effects of hydrophilic organic solvents on CYP3A-mediated drug-drug interaction in vitro","volume":"25","author":"Iwase","year":"2006","journal-title":"Hum. Exp. Toxicol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1021\/js9601849","article-title":"Influence of polyethylene glycol and acetone on the in vitro biotransformation of tamoxifen and alprazolam by human liver microsomes","volume":"85","author":"Greenblatt","year":"1996","journal-title":"J. Pharm. Sci."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1006\/abbi.1997.9964","article-title":"Inhibition of coumarin 7-hydroxylase activity in human liver microsomes","volume":"341","author":"Draper","year":"1997","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_105","first-page":"1","article-title":"Effect of common organic solvents on in vitro cytochrome P450-mediated metabolic activities in human liver microsomes","volume":"26","author":"Chauret","year":"1998","journal-title":"Drug Metab. Dispos."},{"key":"ref_106","first-page":"207","article-title":"Evaluation of the selectivity of in vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities","volume":"26","author":"Hickman","year":"1998","journal-title":"Drug Metab. Dispos."},{"key":"ref_107","first-page":"246","article-title":"Effect of methanol, ethanol, dimethyl sulfoxide, and acetonitrile on in vitro activities of cDNA-expressed human cytochromes P-450","volume":"27","author":"Busby","year":"1999","journal-title":"Drug Metab. Dispos."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1080\/004982599238056","article-title":"Flunitrazepam oxidative metabolism in human liver microsomes: Involvement of CYP2C19 and CYP3A4","volume":"29","author":"Coller","year":"1999","journal-title":"Xenobiotica"},{"key":"ref_109","first-page":"38","article-title":"Stimulation of tolbutamide hydroxylation by acetone and acetonitrile in human liver microsomes and in a cytochrome P-450 2C9-reconstituted system","volume":"28","author":"Palamanda","year":"2000","journal-title":"Drug Metab. Dispos."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/jms.1239","article-title":"In vitro interaction cocktail assay for nine major cytochrome P450 enzymes with 13 probe reactions and a single LC\/MSMS run: Analytical validation and testing with monoclonal anti-CYP antibodies","volume":"42","author":"Tolonen","year":"2007","journal-title":"J. Mass Spectrom."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jpba.2008.05.011","article-title":"An automated, high-throughput, 384 well Cytochrome P450 cocktail IC50 assay using a rapid resolution LC\u2013MS\/MS end-point","volume":"48","author":"Youdim","year":"2008","journal-title":"J. Pharmaceut. Biomed."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2174\/187231211794455235","article-title":"An In Vitro, High Throughput, Seven CYP Cocktail Inhibition Assay for the Evaluation of New Chemical Entities Using LC-MS\/MS","volume":"5","author":"Otten","year":"2011","journal-title":"Drug Metab. Lett."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"520","DOI":"10.2133\/dmpk.DMPK-12-RG-014","article-title":"Reliable high-throughput method for inhibition assay of 8 cytochrome P450 isoforms using cocktail of probe substrates and stable isotope-labeled internal standard","volume":"27","author":"Kozakai","year":"2012","journal-title":"Drug Metab. Pharmacokinet."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/aps.2016.10","article-title":"An improved substrate cocktail for assessing direct inhibition and time-dependent inhibition of multiple cytochrome P450s","volume":"37","author":"Chen","year":"2016","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1124\/dmd.110.033894","article-title":"Effect of Regular Organic Solvents on Cytochrome P450-Mediated Metabolic Activities in Rat Liver Microsomes: Fig. 1","volume":"38","author":"Li","year":"2010","journal-title":"Drug Metab. Dispos."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/00498250903337392","article-title":"Effects of organic solvents on the time-dependent inhibition of CYP3A4 by diazepam","volume":"40","author":"Nishiya","year":"2009","journal-title":"Xenobiotica"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1248\/bpb.32.517","article-title":"Effect of Ethanol on S-Warfarin and Diclofenac Metabolism by Recombinant Human CYP2C9.1","volume":"32","author":"Tatsumi","year":"2009","journal-title":"Biol. Pharm. Bull."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1007\/s11095-010-0170-2","article-title":"Effects of Commonly Used Excipients on the Expression of CYP3A4 in Colon and Liver Cells","volume":"27","author":"Tompkins","year":"2010","journal-title":"Pharm. Res."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2174\/1389200054633826","article-title":"Regulation of Hepatic Transporters by Xenobiotic Receptors","volume":"6","author":"Klaassen","year":"2005","journal-title":"Curr. Drug Metab."},{"key":"ref_120","first-page":"449","article-title":"Overview of enzymes of drug metabolism","volume":"24","author":"Meyer","year":"1996","journal-title":"J. Pharmacokinet. Phar."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2174\/1389200003338947","article-title":"Sense and Nonsense in the Prediction of Drug-Drug Interactions","volume":"1","author":"Lin","year":"2000","journal-title":"Curr. Drug Metab."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.2165\/00003088-200342150-00003","article-title":"Role of Orphan Nuclear Receptors in the Regulation of Drug-Metabolising Enzymes","volume":"42","author":"Wang","year":"2003","journal-title":"Clin. Pharmacokinet."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0092-8674(00)80900-9","article-title":"An Orphan Nuclear Receptor Activated by Pregnanes Defines a Novel Steroid Signaling Pathway","volume":"92","author":"Kliewer","year":"1998","journal-title":"Cell"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1172\/JCI3703","article-title":"The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions","volume":"102","author":"Lehmann","year":"1998","journal-title":"J. Clin. Investig."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1093\/toxsci\/kfr178","article-title":"Acetyl Tributyl Citrate, the Most Widely Used Phthalate Substitute Plasticizer, Induces Cytochrome P450 3A through Steroid and Xenobiotic Receptor","volume":"123","author":"Takeshita","year":"2011","journal-title":"Toxicol. Sci."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/21\/8224\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:28:38Z","timestamp":1760178518000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/21\/8224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,3]]},"references-count":125,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2020,11]]}},"alternative-id":["ijms21218224"],"URL":"https:\/\/doi.org\/10.3390\/ijms21218224","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,3]]}}}